Navigation Links
Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Date:6/2/2009

NEW YORK, June 2 /PRNewswire/ -- Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will make a presentation titled "Cynvec: Breakthrough Oncolytic Viral Vector Therapy with Sindbis" at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry. Mr. Stonebanks' presentation will take place on Wednesday, June 3, 2009 at 10:00 a.m. local time, in Shanghai China. Additional information about the conference can be found at: www.bio-forum.com.

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in the third quarter of 2009. The sindbis vector has demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at www.cynvec.com.


'/>"/>
SOURCE Cynvec LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
2. Cynvec to Present at the BIO National Venture Conference
3. Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
4. Cynvec LLC(SM) to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
5. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
6. ViroPharma to Present at Two June Healthcare Conferences
7. Cynosure Announces Presentations at Upcoming Investor Conferences
8. BioMarin to Present at the Goldman Sachs Healthcare Conference
9. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
10. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2020)... (PRWEB) , ... April 22, 2020 , ... ... equipment for healthcare providers to protect themselves from COVID-19. Virginia has only been ... the Federal Emergency Management Association (FEMA). , As Governor Northam told the Virginia ...
(Date:4/22/2020)... ANN ARBOR, Mich. (PRWEB) , ... April 21, ... ... help clinical researchers continue their work through COVID-19. Many clinical trial teams are ... their work online. Ripple Science wants to help researchers continue their research during ...
(Date:4/7/2020)... YARDLEY, Pa. (PRWEB) , ... April 06, 2020 ... ... performance, and process solutions for the life sciences industry, has announced the release ... situation developing quickly, our top priority is the health and safety of our ...
(Date:4/1/2020)... ... March 31, 2020 , ... ... developed a method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables that ... reaction volumes, increased samples per run, and standard, affordable laboratory equipment, a ...
Breaking Biology Technology:
(Date:5/6/2020)... Md. and LEXINGTON, Mass. (PRWEB) , ... May 06, 2020 , ... ... Hemanext Inc. , a privately held medical technology company dedicated to improving the quality, ... announce a new partnership that will help SCDAA deliver on its mission and meet ...
(Date:5/1/2020)... ... May 01, 2020 , ... More than 600 people undergo genetic counseling and ... which is led by two genetic counselors. , My Gene Counsel , a ... up with UConn’s High Rick Program to ensure that UConn’s patients who have undergone ...
(Date:4/26/2020)... ... 2020 , ... SECO , a leading company in ... by Fondo Italiano d’Investimento SGR, today announced a partnership with IBD, an innovative ... new non-invasive pulmonary ventilator created in response to the current health emergency of ...
Breaking Biology News(10 mins):